Trials / Completed
CompletedNCT00069264
Study of E7389 in Patients With Advanced Solid Tumors
A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7389 | E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle. |
Timeline
- Start date
- 2003-09-01
- Primary completion
- 2005-03-01
- Completion
- 2005-07-01
- First posted
- 2003-09-24
- Last updated
- 2011-12-20
- Results posted
- 2011-12-20
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00069264. Inclusion in this directory is not an endorsement.